Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer-Reference-Cited by-同舟云学术

Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer

Published:2021-02-01 Issue:2 Volume:7 Page:246
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Van Poznak Catherine H.¹,Unger Joseph M.²,Darke Amy K.²,Moinpour Carol³,Bagramian Robert A.⁴,Schubert Mark M.⁵,Hansen Lisa Kathryn⁶,Floyd Justin D.⁷,Dakhil Shaker R.⁸,Lew Danika L.²,Wade James Lloyd⁹,Fisch Michael J.¹⁰,Henry N. Lynn¹,Hershman Dawn L.¹¹,Gralow Julie¹²

Affiliation:

1. Department of Internal Medicine, University of Michigan, Ann Arbor

2. SWOG Cancer Research Network Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington

3. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

4. School of Dentistry, University of Michigan, Ann Arbor

5. University of Washington School of Dentistry, Seattle

6. Clinical Program Specialists, Legacy Good Samaritan Hospital, Portland, Oregon

7. Heartland NCORP (National Cancer Institute Community Oncology Research Program)/Cancer Care Specialists of Illinois, Swansea

8. Wichita NCORP/Cancer Center of Kansas, Wichita

9. Cancer Care Specialists of Illinois, Decatur

10. Department of General Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas

11. Columbia University Medical Center, New York, New York

12. University of Washington, Seattle, Cancer Care Alliance, Seattle

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2773839/jamaoncology_van_poznak_2020_oi_200097_1613590894.0333.pdf

Reference26 articles.

1. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology–Cancer Care Ontario focused guideline update.;Van Poznak;J Clin Oncol,2017

2. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update.;Anderson;J Clin Oncol,2018

3. Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents.;Poon;Clin Oncol (R Coll Radiol),2013

4. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.;Khan;J Bone Miner Res,2015

5. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.;von Elm;Lancet,2007

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Self-assembly nanoparticles potentiate in-situ tumor vaccine of radiotherapy by regulating tumor immunogenicity and tumor-associated macrophages;Chemical Engineering Journal;2024-10

2. Beyond cancer treatment: dermo-aesthetic and other wellness recommendations for breast cancer patients;Clinical and Translational Oncology;2024-08-29

3. Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel;Blood Cancer Journal;2024-08-27

4. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw;Supportive Care in Cancer;2024-07-25

5. Approach to Bone Health in the Patient With Breast Cancer;The Journal of Clinical Endocrinology & Metabolism;2024-06-12